Glaukos publishes investor presentation on interventional glaucoma, keratoconus treatment pipeline

Glaukos Corp

Glaukos Corp

GKOS

0.00
  • Glaukos highlighted 2025 topline growth of more than 30% with a 10-year revenue CAGR above 20%.
  • Interventional glaucoma strategy centered on iDose TR, designed to deliver up to 3 years of travoprost, with FDA clearance for re-administration in January 2026.
  • Clinical metrics cited for iDose TR included 81% of subjects free of IOP-lowering topical medication at 12 months, with 70% well-controlled on same or fewer medications at 3 years.
  • Pipeline focus included iDose TRIO in Phase 3b, iDose TREX in Phase 2b/3, with iStent infinite positioned for broader use via a label-expansion PMA study.
  • Keratoconus franchise update featured Epioxa, described as first FDA-approved epithelium-on corneal cross-linking treatment, now commercially available since March 2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Glaukos Corporation published the original content used to generate this news brief on May 04, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.